Dyne Therapeutics Receives Orphan Drug Designation in Japan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Should l Buy DYN?
Dyne Therapeutics announced that the Ministry of Health, Labour and Welfare, MHLW, in Japan has granted Orphan Drug designation, ODD, for zeleciment basivarsen, for the treatment of myotonic muscular dystrophy type 1, DM1. Z-basivarsen is currently being evaluated in the Phase 1/2 ACHIEVE clinical trial in individuals with DM1. "By targeting the underlying biology of DM1, z-basivarsen has shown early and sustained improvements in myotonia, muscle strength and function, with a favorable safety profile," said Doug Kerr, M.D., Ph.D., chief medical officer of Dyne. "This designation in Japan, alongside those already granted in the U.S. and Europe, emphasizes the urgent need for new therapies and highlights the potential of z-basivarsen to deliver meaningful functional improvement for people living with DM1."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DYN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DYN
Wall Street analysts forecast DYN stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.620
Low
17.00
Averages
39.33
High
60.00
Current: 15.620
Low
17.00
Averages
39.33
High
60.00
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dyne Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Dyne Therapeutics reported a Q4 GAAP EPS of -$0.76, beating market expectations by $0.02, indicating some improvement in financial management that could enhance investor confidence.
- Cash Reserves: As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $1.1 billion, ensuring sufficient funding for operations expected to last into Q1 2028, which is crucial for ongoing projects.
- Future Outlook: Dyne Therapeutics anticipates that its ample cash reserves will support upcoming clinical trials and product development, further driving growth potential in the biopharmaceutical sector.
- Market Reaction: Oppenheimer upgraded Dyne's rating based on the upcoming clinical trial readout from Avidity, reflecting a positive market sentiment regarding the company's future prospects.
See More
Dyne Therapeutics Advances DMD Treatment Progress
- Accelerated Approval Plan: Dyne Therapeutics is set to submit a U.S. Accelerated Approval application for z-rostudirsen in Q2 2026, with a potential launch in Q1 2027, which will provide urgently needed new therapies for DMD patients and significantly enhance the company's market position in this area.
- Clinical Trial Results: The z-rostudirsen demonstrated significant efficacy in the Registrational Expansion Cohort of the DELIVER trial, achieving a muscle content-adjusted dystrophin expression of 5.46% of normal at six months, laying a solid foundation for subsequent clinical applications.
- Strong Financial Position: As of December 31, 2025, Dyne reported cash and cash equivalents of $1.1 billion, expected to fund operations into Q1 2028, ensuring the continued advancement of its R&D projects.
- Multi-Faceted R&D Strategy: Dyne is advancing four development candidates for DMD using the FORCE platform's technological advantages, aiming to provide broader treatment options for various types of DMD patients, further solidifying its leadership in the field of genetically driven neuromuscular diseases.
See More
Palo Alto Investors Increases Stake in Dyne Therapeutics
- Share Increase: Palo Alto Investors LP disclosed an increase of 209,523 shares in Dyne Therapeutics in its 13F filing for the quarter ended December 31, 2025, representing an estimated $3.97 million trade, indicating confidence in the company.
- Value Growth: The fund's quarter-end position in Dyne increased in value by $12.82 million, reflecting not only the additional shares but also price appreciation, suggesting positive market expectations for Dyne.
- Stake Enhancement: This purchase raised Palo Alto's stake in Dyne to 4.01%, further solidifying its investment strategy in the biotechnology sector and demonstrating optimism about the company's future prospects.
- Market Performance: As of February 17, 2026, Dyne Therapeutics shares were priced at $15.28, with a one-year total return of 10.9%, although underperforming the S&P 500 by 2.07 percentage points, still indicating some market resilience.
See More
Sarepta Therapeutics Reports Earnings Miss and Management Transition
- Earnings Miss: Sarepta Therapeutics reported an adjusted loss of $3.58 per share, significantly worse than Wall Street's estimate of a $1.31 loss, while sales reached $442.93 million, exceeding the consensus of $391.92 million; however, sales fell 33% year-over-year, primarily due to a $273.8 million drop in Elevidys net product revenue following the company's decision to suspend shipments to non-ambulatory patients in June 2025.
- Management Transition: CEO Douglas Ingram announced his plan to retire by the end of 2026 or upon the appointment of his successor, as disclosed in an SEC filing, prompting the company to initiate a search for a new CEO, which could lead to increased stock volatility in the near term.
- Analyst View: While the company has guided for stable PMO revenue in 2026, analyst Sami Corwin expresses hesitation due to concerns over the marketing authorization of Vyondys 53 and Amondys 45 following the recent failure of the ESSENCE trial; William Blair reiterates a Market Perform rating, viewing limited near-term upside potential for the stock.
- Technical Analysis: The stock is currently trading 3.5% below its 20-day simple moving average and 9.8% below its 100-day SMA, indicating a bearish trend in the short to medium term, with an RSI of 50.00 suggesting neutral market sentiment, while a MACD of -0.10 below its signal line at -0.05 indicates bearish pressure, with key resistance at $20.00 and support at $15.00.
See More
Dyne Therapeutics to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Dyne Therapeutics is set to participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, in Boston, showcasing its advancements in genetically driven neuromuscular diseases, which is expected to attract investor interest.
- Biotech Summit Engagement: The company will hold meetings at the Jefferies Biotech on the Beach Summit in Miami on March 10 and 11, 2026, further enhancing interactions with potential investors and boosting market confidence.
- Virtual Forum Participation: Dyne will engage in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026, leveraging virtual platforms to expand its reach and connect with a broader investor audience.
- Clinical Program Advancements: Dyne is focused on developing therapeutics for Duchenne muscular dystrophy and myotonic dystrophy type 1, aiming to address the root causes of these diseases and improve patient quality of life, highlighting the company's strategic significance in the biopharmaceutical sector.
See More
Dyne Announces Positive Results from DELIVER Trial for DMD at MDA Conference
- DELIVER Trial Results: Dyne showcased positive outcomes from the DELIVER trial at the 2026 MDA Conference, demonstrating that z-rostudirsen significantly improved muscle function in DMD patients, particularly in long-term cardiopulmonary function, further validating the efficacy of its FORCE™ platform.
- Clinical Trial Design: The company will present the Phase 3 trial design for z-basivarsen in DM1, which is expected to set a new standard in the field, highlighting Dyne's forward-thinking and innovative approach to treating neuromuscular diseases.
- Multiple Presentations: Dyne will conduct five presentations, including three oral reports covering DMD, DM1, and Pompe disease, showcasing its robust pipeline in neuromuscular disorders and enhancing investor confidence.
- Cutting-Edge Data Release: The company will also release new preclinical data for DYNE-401 in Pompe disease, indicating potential functional improvements with infrequent dosing, further solidifying Dyne's leadership position in neuromuscular disease therapies.
See More
Dyne Therapeutics Q4 Earnings Beat Expectations
- Earnings Performance: Dyne Therapeutics reported a Q4 GAAP EPS of -$0.76, beating market expectations by $0.02, indicating some improvement in financial management that could enhance investor confidence.
- Cash Reserves: As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $1.1 billion, ensuring sufficient funding for operations expected to last into Q1 2028, which is crucial for ongoing projects.
- Future Outlook: Dyne Therapeutics anticipates that its ample cash reserves will support upcoming clinical trials and product development, further driving growth potential in the biopharmaceutical sector.
- Market Reaction: Oppenheimer upgraded Dyne's rating based on the upcoming clinical trial readout from Avidity, reflecting a positive market sentiment regarding the company's future prospects.
See More
Dyne Therapeutics Advances DMD Treatment Progress
- Accelerated Approval Plan: Dyne Therapeutics is set to submit a U.S. Accelerated Approval application for z-rostudirsen in Q2 2026, with a potential launch in Q1 2027, which will provide urgently needed new therapies for DMD patients and significantly enhance the company's market position in this area.
- Clinical Trial Results: The z-rostudirsen demonstrated significant efficacy in the Registrational Expansion Cohort of the DELIVER trial, achieving a muscle content-adjusted dystrophin expression of 5.46% of normal at six months, laying a solid foundation for subsequent clinical applications.
- Strong Financial Position: As of December 31, 2025, Dyne reported cash and cash equivalents of $1.1 billion, expected to fund operations into Q1 2028, ensuring the continued advancement of its R&D projects.
- Multi-Faceted R&D Strategy: Dyne is advancing four development candidates for DMD using the FORCE platform's technological advantages, aiming to provide broader treatment options for various types of DMD patients, further solidifying its leadership in the field of genetically driven neuromuscular diseases.
See More
Palo Alto Investors Increases Stake in Dyne Therapeutics
- Share Increase: Palo Alto Investors LP disclosed an increase of 209,523 shares in Dyne Therapeutics in its 13F filing for the quarter ended December 31, 2025, representing an estimated $3.97 million trade, indicating confidence in the company.
- Value Growth: The fund's quarter-end position in Dyne increased in value by $12.82 million, reflecting not only the additional shares but also price appreciation, suggesting positive market expectations for Dyne.
- Stake Enhancement: This purchase raised Palo Alto's stake in Dyne to 4.01%, further solidifying its investment strategy in the biotechnology sector and demonstrating optimism about the company's future prospects.
- Market Performance: As of February 17, 2026, Dyne Therapeutics shares were priced at $15.28, with a one-year total return of 10.9%, although underperforming the S&P 500 by 2.07 percentage points, still indicating some market resilience.
See More
Sarepta Therapeutics Reports Earnings Miss and Management Transition
- Earnings Miss: Sarepta Therapeutics reported an adjusted loss of $3.58 per share, significantly worse than Wall Street's estimate of a $1.31 loss, while sales reached $442.93 million, exceeding the consensus of $391.92 million; however, sales fell 33% year-over-year, primarily due to a $273.8 million drop in Elevidys net product revenue following the company's decision to suspend shipments to non-ambulatory patients in June 2025.
- Management Transition: CEO Douglas Ingram announced his plan to retire by the end of 2026 or upon the appointment of his successor, as disclosed in an SEC filing, prompting the company to initiate a search for a new CEO, which could lead to increased stock volatility in the near term.
- Analyst View: While the company has guided for stable PMO revenue in 2026, analyst Sami Corwin expresses hesitation due to concerns over the marketing authorization of Vyondys 53 and Amondys 45 following the recent failure of the ESSENCE trial; William Blair reiterates a Market Perform rating, viewing limited near-term upside potential for the stock.
- Technical Analysis: The stock is currently trading 3.5% below its 20-day simple moving average and 9.8% below its 100-day SMA, indicating a bearish trend in the short to medium term, with an RSI of 50.00 suggesting neutral market sentiment, while a MACD of -0.10 below its signal line at -0.05 indicates bearish pressure, with key resistance at $20.00 and support at $15.00.
See More
Dyne Therapeutics to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Dyne Therapeutics is set to participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026, in Boston, showcasing its advancements in genetically driven neuromuscular diseases, which is expected to attract investor interest.
- Biotech Summit Engagement: The company will hold meetings at the Jefferies Biotech on the Beach Summit in Miami on March 10 and 11, 2026, further enhancing interactions with potential investors and boosting market confidence.
- Virtual Forum Participation: Dyne will engage in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026, leveraging virtual platforms to expand its reach and connect with a broader investor audience.
- Clinical Program Advancements: Dyne is focused on developing therapeutics for Duchenne muscular dystrophy and myotonic dystrophy type 1, aiming to address the root causes of these diseases and improve patient quality of life, highlighting the company's strategic significance in the biopharmaceutical sector.
See More
Dyne Announces Positive Results from DELIVER Trial for DMD at MDA Conference
- DELIVER Trial Results: Dyne showcased positive outcomes from the DELIVER trial at the 2026 MDA Conference, demonstrating that z-rostudirsen significantly improved muscle function in DMD patients, particularly in long-term cardiopulmonary function, further validating the efficacy of its FORCE™ platform.
- Clinical Trial Design: The company will present the Phase 3 trial design for z-basivarsen in DM1, which is expected to set a new standard in the field, highlighting Dyne's forward-thinking and innovative approach to treating neuromuscular diseases.
- Multiple Presentations: Dyne will conduct five presentations, including three oral reports covering DMD, DM1, and Pompe disease, showcasing its robust pipeline in neuromuscular disorders and enhancing investor confidence.
- Cutting-Edge Data Release: The company will also release new preclinical data for DYNE-401 in Pompe disease, indicating potential functional improvements with infrequent dosing, further solidifying Dyne's leadership position in neuromuscular disease therapies.
See More
